Investigational / not FDA-approved

Kisspeptin-10

KISS1R agonist decapeptide (KP-10) — ≠ KP-54; human LH physiology; no consumer fertility label assumed.

Editorial review:

What evidence says

Evidence snapshot

This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.

Identity lock. Kisspeptin-10 (KP-10; metastin 45–54) is the C-terminal decapeptide of kisspeptin that activates the KISS1R/GPR54 receptor. Human KP-10 sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2. PubChem CID 25240297; formula C63H83N17O14 / MW 1302.4; CAS 374675-21-5. ≠ Kisspeptin-54 (longer endogenous fragment used in many Dhillo/Jayasena clinical papers — related pathway, different peptide length). ≠ gonadorelin / GnRH, ≠ hCG/hMG. This drawer marks papers. It is not use advice.

Bottom line

Human experimental medicine shows KP-10 stimulates LH (and in some contexts testosterone) with sexual dimorphism and disease-context differences (e.g. men with type 2 diabetes). Longer kisspeptin-54 has a richer trigger/amenorrhea clinical set — cite as related object, not automatic KP-10 proof. Antidoping detection methods exist. No approved consumer fertility-peptide product should be assumed from these physiology papers alone.

Papers

Human KP-10 administration (identity-matched)

PMID 21632807 — George 2011

Tested: kisspeptin-10 as a potent stimulator of LH that increases pulse frequency in men (human experimental medicine).

Does not show: an approved infertility drug label for KP-10 vials, or equivalence to kisspeptin-54 IVF-trigger programs.

PMID 21976724 — Jayasena 2011

Tested: effects of kisspeptin-10 on reproductive hormone release showing sexual dimorphism in humans.

Does not show: that female and male responses are interchangeable, or a consumer dosing license (never provided here).

PMID 23153270 — George 2013

Tested: kisspeptin-10 stimulating serum testosterone and LH in men with type 2 diabetes (pathophysiology/exploratory endocrine study).

Does not show: a diabetes or hypogonadism approval package for KP-10.

PMID 38978171 — Colpaert 2024

Tested: analytical detection of kisspeptin-10 in urine (antidoping / LC-HRMS method development).

Does not show: clinical efficacy.

Related kisspeptin-54 clinical object (NOT automatic KP-10 proof)

PMID 16174713 — Dhillo 2005

Tested: kisspeptin-54 stimulating the HPG axis in human males — KP-54 ≠ KP-10.

Does not show: KP-10 identity match; pathway context only.

PMID 24517142 — Jayasena 2014

Tested: intravenous infusion of kisspeptin-54 increasing LH pulsatility in women with hypothalamic amenorrhoea — KP-54 object.

Does not show: KP-10 proof by substitution.

PMID 26192876 — Abbara 2015

Tested: efficacy of kisspeptin-54 to trigger oocyte maturation in women at high OHSS risk during IVF — KP-54 clinical object.

Does not show: that KP-10 is an approved IVF trigger.

PMID 28112678 — Comninos 2017

Tested: kisspeptin modulating sexual and emotional brain processing in humans (kisspeptin pathway neuroimaging/experimental medicine; length framing as reported in paper — keep pathway-level, not vial claims).

Does not show: a libido-drug approval for KP-10.

Pathway reviews

PMID 32427949 — Navarro 2020

Tested: review of metabolic regulation of kisspeptin linking energy balance and reproduction.

Does not show: primary KP-10 RCT data.

PMID 30205368 — Trevisan 2018

Tested: review of the kisspeptin/GPR54 system in human reproduction.

Does not show: product-specific KP-10 approval.

What is not established

That KP-10 equals KP-54 clinical results. Approved consumer fertility or “libido peptide” status for KP-10. Long-term safety of repeated unregulated KP-10 use. Product identity for gray-market kisspeptin preparations. This drawer does not provide use advice, schedules, or sourcing.

Selected sources

21632807 21976724 23153270 38978171 16174713 24517142 26192876 28112678 32427949 30205368

What people discuss

Reported experiences

Reported topics are not established benefits.

Watch for

Risks and unknowns

Context matters. Approval of one medicine, formulation, or use does not establish approval of products sold online or other uses. This page is educational and does not provide dosing or treatment advice.

Member discussion

Compare experiences with care.

Before posting: Describe firsthand observations and uncertainty. Do not prescribe, arrange transactions, or post private health information.

◎Verified members

Join the discussion

Verified members can contribute to compound conversations.

No approved member reports yet. Thoughtful first contributions are welcome.